BRD4 and lymphoma: Utilizing PG analogs, Li et al. developed SJ995973, which exhibited exceptional stability and effective degradation of BRD4 at low picomolar concentrations in MV4-11 cells.73 In addition, they further enhanced the cell permeability of PROTACs in AML cell lines through an amide-to-ester substitution approach.456 Currently, RNK05047, a BRD4 degrader, has entered a Phase I/II clinical trial for advanced solid tumors and lymphomas.